| Assessment Status | Rapid Review Complete |
| HTA ID | 20057 |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | As monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 15/12/2020 |
| Rapid review completed | 13/01/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that nivolumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.